Merck's Proactive Strategy to Capture the Global PrEP Market

Merck & Co. (MRK) has taken an unprecedented step by entering into voluntary licensing agreements for alimatravir (MK-8527), its investigational once-monthly oral pre-exposure prophylaxis (PrEP) for HIV, while it is still in Phase 3 clinical trials. This marks the first time a pharmaceutical company has proactively partnered with generic manufacturers to produce the drug in advance of regulatory approval in the global HIV treatment market. This demonstrates Merck's strong commitment to rapidly gaining market leadership by ensuring affordable generic versions are immediately available in low-income countries upon regulatory approval. The agreement with seven major generic manufacturers in Africa and India is structured as royalty-free, which is expected to significantly improve access to the medication.

Positioning Against Gilead's Yeztugo

Merck's bold move is a strategic effort to disrupt the market dominance of Gilead Sciences (GILD) and its long-acting injectable, Yeztugo (lenacapavir). Yeztugo, a capsid inhibitor, has demonstrated nearly 100% efficacy in preventing HIV infection in the PURPOSE 1 and PURPOSE 2 Phase 3 trials with only two injections per year, establishing itself as a new standard of care in HIV prevention. In response, Merck is positioning alimatravir, an NRTTI, as a convenient once-monthly oral formulation, aiming to capture a segment of the market that prioritizes ease of administration. By leveraging its superior convenience and cost-effective generic pricing, Merck intends to reshape the HIV prevention market currently dominated by Gilead.

Validating a New NRTTI Candidate to Overcome Past Failures

Merck previously experienced a setback when it had to discontinue the development of islatravir (MK-8507), another NRTTI, as a monthly PrEP due to safety concerns observed during clinical trials. High doses of the drug caused a significant decrease in total lymphocyte and CD4+ T-cell counts in some patients, leading to the termination of the program. However, the current alimatravir candidate has been designed to address the safety issues encountered with the previous compound, and has demonstrated a favorable safety profile in Phase 2 clinical trials. The company is currently conducting large-scale Phase 3 trials, EXPrESSIVE-10 and EXPrESSIVE-11, in Africa and Latin America to further validate the drug's safety and efficacy.

Securing Global Supply Chains and Enhancing Ethical Values Through Early Licensing

Merck has partnered with global generic manufacturers, including Aspen Pharmacare of South Africa and Cipla of India, to establish a supply chain for generic versions of alimatravir in 129 low- and middle-income countries (LMICs), including sub-Saharan Africa. Typically, establishing a generic distribution network after drug approval can take several years. By proactively securing supply agreements during the clinical phase, Merck aims to significantly shorten the time to market. This approach aligns with the company's commitment to global health by contributing to the reduction of HIV infection rates in developing countries, while also enhancing its brand reputation as a responsible pharmaceutical company. Furthermore, this early preparation ensures that the company can meet the anticipated surge in demand for generic versions immediately after approval.

Merck's Potential for Market Penetration in the Oral vs. Injectable Competition

From an investment perspective, Merck's strategy is a key element in diversifying its HIV prevention and treatment portfolio and securing sustainable growth. Merck is currently collaborating with Gilead to co-develop a once-weekly HIV treatment regimen combining islatravir and lenacapavir, demonstrating a unique relationship of both cooperation and competition. In the prevention market, with the shift from daily oral medications like Truvada and Descovy to long-acting injectables, Merck's once-monthly oral formulation has the potential to capture a significant market share. While the monthly regimen may present challenges in terms of patient adherence compared to the twice-yearly injection, the early establishment of a distribution network is expected to enhance its initial market penetration.